These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 12389338

  • 1. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin?
    Cohen E, Almog S, Staruvin D, Garty M.
    Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338
    [Abstract] [Full Text] [Related]

  • 2. Effect of exenatide on the steady-state pharmacokinetics of digoxin.
    Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, Lim M, Mace KF, Wise SD.
    J Clin Pharmacol; 2005 Sep; 45(9):1032-7. PubMed ID: 16100297
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).
    Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I.
    Clin Pharmacol Ther; 1999 Oct; 66(4):338-45. PubMed ID: 10546917
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
    Denker AE, Morelli G, Vessey LK, Li S, Yuan J, Dunbar S, Lewis NM, Taggart W, Wagner JA.
    Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic interaction of sparfloxacin and digoxin.
    Johnson RD, Dorr MB, Hunt TL, Conway S, Talbot GH.
    Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
    [Abstract] [Full Text] [Related]

  • 6. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers.
    Stangier J, Su CA, Hendriks MG, van Lier JJ, Sollie FA, Oosterhuis B, Jonkman JH.
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1373-9. PubMed ID: 11185636
    [Abstract] [Full Text] [Related]

  • 7. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW, Charland SL, Shaw LM, Kobrin S, Goldfarb S, Stanek EJ, Spinler SA.
    Pharmacotherapy; 1997 Dec; 17(3):584-90. PubMed ID: 9165563
    [Abstract] [Full Text] [Related]

  • 8. Absence of an interaction between tigecycline and digoxin in healthy men.
    Zimmerman JJ, Harper DM, Matschke K, Speth JL, Raible DG, Fruncillo RJ.
    Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
    [Abstract] [Full Text] [Related]

  • 9. The serum digoxin concentration: ten questions to ask.
    Cauffield JS, Gums JG, Grauer K.
    Am Fam Physician; 1997 Aug; 56(2):495-503, 509-10. PubMed ID: 9262530
    [Abstract] [Full Text] [Related]

  • 10. A possible interaction of potential clinical interest between digoxin and acarbose.
    Serrano JS, Jiménez CM, Serrano MI, Balboa B.
    Clin Pharmacol Ther; 1996 Nov; 60(5):589-92. PubMed ID: 8941033
    [Abstract] [Full Text] [Related]

  • 11. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 12. Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers.
    Tarral A, Francheteau P, Guerret M.
    Pharmacotherapy; 1997 Nov; 17(4):791-5. PubMed ID: 9250559
    [Abstract] [Full Text] [Related]

  • 13. Absence of a clinically relevant interaction between etanercept and digoxin.
    Zhou H, Parks V, Patat A, Le Coz F, Simcoe D, Korth-Bradley J.
    J Clin Pharmacol; 2004 Nov; 44(11):1244-51. PubMed ID: 15496642
    [Abstract] [Full Text] [Related]

  • 14. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.
    Mahgoub AA, El-Medany AH, Abdulatif AS.
    Saudi Med J; 2002 Jun; 23(6):725-31. PubMed ID: 12070557
    [Abstract] [Full Text] [Related]

  • 15. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
    Liu F, Vessey L, Wenning L, Connolly S, Buckland M, Johnson-Levonas AO, Denker A, Wagner JA, Lai E.
    J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
    [Abstract] [Full Text] [Related]

  • 16. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.
    Vaz da Silva M, Costa R, Soares E, Maia J, Falcão A, Almeida L, Soares da Silva P.
    Fundam Clin Pharmacol; 2009 Aug; 23(4):509-14. PubMed ID: 19500154
    [Abstract] [Full Text] [Related]

  • 17. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
    Sarich TC, Schützer KM, Wollbratt M, Wall U, Kessler E, Eriksson UG.
    J Clin Pharmacol; 2004 Aug; 44(8):935-41. PubMed ID: 15286098
    [Abstract] [Full Text] [Related]

  • 18. Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin.
    Di Cicco RA, Miller AK, Patterson S, Freed MI.
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1516-21. PubMed ID: 11185675
    [Abstract] [Full Text] [Related]

  • 19. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha).
    Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton JL, Annesley T, Aaronson KD, Bleske BE.
    J Clin Pharmacol; 2003 Jun; 43(6):637-42. PubMed ID: 12817526
    [Abstract] [Full Text] [Related]

  • 20. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
    Shoaf SE, Ohzone Y, Ninomiya S, Furukawa M, Bricmont P, Kashiyama E, Mallikaarjun S.
    J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.